Stock Details
AZN is AstraZeneca PLC's stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 64.83$. Average daily volumn in 3 months 6.94M. Market cap 200.04B



Stock symbol : AZN. Exchange : NasdaqGS. Currency : USD
Lastest price : 64.55$. Total volume : 1.04M. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

AstraZeneca PLC (AZN)
Last Price
64.55$
Change
-1.52
Volume
1.04M

Previous Close66.07
Open64.10
Day Range64.07-64.57
Bid64.01 x 1.2k
Ask63.99 x 1.1k
Volume1.04M
Average Volume6.94M
Market Cap200.04B
Beta0.12
52 Week Range53.63-71.70
Trailing P/EN/A
Foward P/E16.90
Dividend (Yield %)2.18%
Ex-Dividend Date2022-02-24



Financial Details


According to AstraZeneca PLC's financial reports the company's revenue in 2021 were 37.42B an increase( +42.31%) over the years 2020 revenue that were of 26.62B. In 2021 the company's total earnings were 112M while total earnings in 2020 were 3.2B(-96.27%).


Loading ...



Organization

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolis... m diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Market Cap:
200.04B
Revenue:
37.42B
Total Assets:
105.36B
Total Cash:
6.33B


News about "AstraZeneca PLC"

Oxford Biomedica, AstraZeneca Extend COVID-19 Vaccine Manufacturing Partnership

Source from : Nasdaq - 14 hours ago

Oxford Biomedica plc (OXB.L) said that it has signed a new three year master services & development agreement with AstraZeneca UK Ltd which would facilitate potential future manufacturing ...See details»


spire-wealth-management-trims-position-in-astrazeneca-plc-nasdaqazn-image

Spire Wealth Management Trims Position in AstraZeneca PLC (NASDAQ:AZN)

Source from : Defense World - 11 hours ago

Spire Wealth Management cut its holdings in shares of AstraZeneca PLC (NASDAQ:AZN โ€“ Get Rating) by 18.0% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 10,219 ...See details»


skorea-authorises-astrazeneca-covid-therapy-evusheld-for-vulnerable-people-image

S.Korea authorises AstraZeneca COVID therapy Evusheld for vulnerable people

Source from : Reuters - 1 days ago

South Korea on Thursday authorised AstraZeneca PLC's antibody-based therapy for preventing COVID-19 infection in people with a poor immune response, increasing its options as it works to ease the ...See details»


astrazeneca-signs-new-three-year-deal-with-oxford-biomedica-for-covid-shot-image

AstraZeneca signs new three-year deal with Oxford Biomedica for COVID shot

Source from : Seeking Alpha - 10 hours ago

U.K.-based biotech Oxford Biomedica (OXBDF) announced on Friday that the company entered into a new three-year partnership with AstraZeneca (AZN) to manufacture the Anglo ...See details»


astrazeneca-imfinzi-plus-chemotherapy-improved-pcr-in-resectable-lung-cancer-quick-facts-image

AstraZeneca: Imfinzi Plus Chemotherapy Improved PCR In Resectable Lung Cancer - Quick Facts

Source from : Nasdaq - 1 days ago

Thursday announced positive high-level results from a planned interim analysis of the AEGEAN Phase III trial that evaluated Imfinzi (durvalumab) plus chemotherapy in resectable non-small cell lung ...See details»


Oxford BioMedica Extends Agreement With AstraZeneca for Covid-19 Vaccine Facility

Source from : MarketWatch - 14 hours ago

By Michael Susin Oxford BioMedica PLC said Friday that it has signed an extended agreement with AstraZeneca UK Ltd. for the use of its facility to ...See details»


small-cap-winners-losers-oxford-biomedica-rises-on-astrazeneca-deal-image

SMALL-CAP WINNERS & LOSERS: Oxford BioMedica rises on AstraZeneca deal

Source from : London South East - 11 hours ago

Oxford BioMedica PLC, up 4.6% at 475.01 pence, 12-month range 414.00p-1,678.00p. The gene and cell therapy company signs a new three-year agreement with AstraZeneca PLC, which will facilitate ...See details»


Oxford BioMedica signs new Covid-19 vaccine deal with AstraZeneca

Source from : Buy - 13 hours ago

Oxford BioMedica PLC on Friday said it has signed a new three year agreement with AstraZeneca PLC, which will facilitate potential future manufacturing opportunities for the FTSE 100-listed ...See details»


wealthcare-advisory-partners-llc-lowers-stock-holdings-in-astrazeneca-plc-nasdaqazn-image

Wealthcare Advisory Partners LLC Lowers Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Source from : Defense World - 2 days ago

Wealthcare Advisory Partners LLC lowered its holdings in shares of AstraZeneca PLC (NASDAQ:AZN โ€“ Get Rating) by 6.0% during the first quarter, according to its most recent disclosure with the ...See details»


what-you-need-to-know-about-astrazeneca-plcs-lonazn-investor-composition-image

What You Need To Know About AstraZeneca PLC's (LON:AZN) Investor Composition

Source from : Yahoo Style Australia - 2 days ago

The big shareholder groups in AstraZeneca PLC ( LON:AZN ) have power over the company. Insiders often own a large ...See details»


caprock-group-inc-has-640000-position-in-astrazeneca-plc-nasdaqazn-image

CAPROCK Group Inc. Has $640,000 Position in AstraZeneca PLC (NASDAQ:AZN)

Source from : ETF Daily News - 7 days ago

CAPROCK Group Inc. increased its stake in shares of AstraZeneca PLC (NASDAQ:AZN โ€“ Get Rating) by 45.5% during the first quarter, HoldingsChannel reports. The institutional investor owned 9,643 shares ...See details»


short-volatility-alert-astrazeneca-plc-image

Short Volatility Alert: AstraZeneca PLC

Source from : Benzinga.com on MSN.com - 9 days ago

On Tuesday, shares of AstraZeneca PLC (NASDAQ: AZN) experienced volatile short activity. After the activity, the stock price went up 2.85% to $62.83. The overall ...See details»


astrazeneca-daiichi-sankyo-enhertu-breast-cancer-drug-recommended-for-eu-approval-image

AstraZeneca-Daiichi Sankyo Enhertu breast cancer drug recommended for EU approval

Source from : MarketWatch on MSN.com - 4 days ago

The decision was based on trial results showing that Enhertu cut the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.See details»


The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies

Source from : Benzinga.com - 4 days ago

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agencyย hasย recommended the approval of Enhertuย (trastuzumab deruxtecan) andย Lynparza (olaparib)ย for breast cancer ...See details»